Loading company
Rallybio Corp
RLYB · Nasdaq · ·
Next earnings: November 5, 2026
$16.86+1.4%Sep 28 close
- 1M
- +0.3%
- 6M
- +109.7%
- 1Y
- +322.3%
- 5Y
- -84.8%
RLYB · Nasdaq · ·
Next earnings: November 5, 2026
$16.86+1.4%Sep 28 close
Rallybio Corp is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $212K | -100.00% |
| Profit | $43.7M | -$9.7M | +550.02% |
| Profit per share | $7.53 | -$0.22 | +3,522.73% |
| Free Cash Flow | -$11.7M | -$15.3M | +23.63% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“In the third quarter, we continued to execute with discipline and focus, advancing our lead program, RLYB116, and achieving a key clinical milestone with the completion of dosing in Cohort 1 in our confirmatory PK/PD Phase 1 study,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Rallybio’s pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Rallybio is headquartered in New Haven, Connecticut.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Rallybio Corp’s Item 2.02 8-K filed November 6, 2025; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Rallybio Corp has no earnings call transcript available.